Sirukumab

Summary

Sirukumab (CHEMBL1743071) is a phase-3 clinical-stage antibody (ATC L04AC15); indicated across 10 conditions including rheumatoid arthritis and immune system disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: L04AC15
• Indications: 10 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743071
Name	Sirukumab
Type	Antibody
Max phase	3
ATC	L04AC15

Also known as: CNTO 136, CNTO-136, CNTO136, Sirukumab, SIRUKUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
immune system disorder	3	MONDO:0005046	EFO:0000540
temporal arteritis	3	MONDO:0008538	EFO:1001209
polymyalgia rheumatica	3	MONDO:0019735	EFO:0008518
lupus nephritis	2	MONDO:0005556	EFO:0005761
major depressive disorder	2	MONDO:0002009	MONDO:0002009
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
asthma	2	MONDO:0004979	MONDO:0004979
cutaneous lupus erythematosus	1	MONDO:0005282	EFO:0003834
systemic lupus erythematosus	1	MONDO:0007915	MONDO:0007915

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	4
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01604343	PHASE3	COMPLETED	A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
NCT01606761	PHASE3	COMPLETED	A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
NCT01689532	PHASE3	COMPLETED	A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
NCT01856309	PHASE3	COMPLETED	Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
NCT02019472	PHASE3	COMPLETED	A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
NCT02531633	PHASE3	TERMINATED	Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
NCT02899026	PHASE3	WITHDRAWN	Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
NCT01273389	PHASE2	COMPLETED	An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
NCT02473289	PHASE2	COMPLETED	An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
NCT02794519	PHASE2	WITHDRAWN	A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
NCT04380961	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
NCT00844909	PHASE1	COMPLETED	A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers
NCT01636557	PHASE1	COMPLETED	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).